News

PharmExec57m
FDA Issues Refusal to File Letter for Axsome’s Novel Fibromyalgia Candidate
FDA concluded that AXS-14’s New Drug Application was not sufficiently complete for substantive review, citing concerns with ...
PharmExec2h
Phase III Trials Show Merck’s Oral PCSK9 Inhibitor Significantly Reduces LDL-Cholesterol in Hyperlipidemia
Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...
PharmExec4h
Valneva’s Single-Shot Chikungunya Vaccine Demonstrates Durable Immune Response in Children
Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...
PharmExec11h
GLP-1 Medications Should Be Paired With Healthy Diet and Exercise: Report
While the medications may reduce diet, the best results will be achieved by building healthy habits alongside the drugs.